TY - JOUR
T1 - High recurrence of device-related adverse events following transvenous lead extraction procedure in patients with cardiac resynchronization devices
AU - Regoli, François
AU - Bongiorni, Maria Grazia
AU - Rordorf, Roberto
AU - Santamaria, Matteo
AU - Klersy, Caterine
AU - Segreti, Luca
AU - De Regibus, Valentina
AU - Moccetti, Tiziano
AU - Conte, Giulio
AU - Caputo, Maria Luce
AU - Auricchio, Angelo
PY - 2016
Y1 - 2016
N2 - Introduction: Little is known about the clinical outcome and recurring system-related adverse events (SAE) in cardiac resynchronization therapy (CRT) patients after transvenous lead extraction (TLE). Methods and results: From January 2009 to June 2014, 256 consecutive CRT patients (mean age 68.3±11.6years, 216 male, 88% in New York Heart Association class II-IV, ejection fraction 35.1±10.8%) were treated at four European institutions with TLE. Indications for TLE included systemic (18%) or local (45%) infection, system malfunction (34%), or other (3%). Demographic, clinical, TLE procedural, and follow-up data were collected retrospectively. Adverse events (AE) were considered as death from any cause, cardiovascular hospitalization, and SAE (SAE included pocket and/or systemic infection, lead malfunction, or pocket haematoma requiring revision). Complete removal was achieved for 607 out of 614 leads (98.9%) by using either manual traction (29%), mechanical (43%) or laser (28%) sheaths. Over a median follow-up of 21 (interquartile range 12-29) months, cumulative incidences of any AE and SAE were 39.8% and 21.5%, respectively. Recurring system malfunction occurred in 23 patients (9.0%), infection in 17 patients (6.6%), and pocket haematoma requiring revision in 15 patients (5.9%). Oral anticoagulation therapy was an independent predictor of both any AE [hazard ratio (HR) 2.09, 95% confidence interval (CI) 1.35-3.22, P
AB - Introduction: Little is known about the clinical outcome and recurring system-related adverse events (SAE) in cardiac resynchronization therapy (CRT) patients after transvenous lead extraction (TLE). Methods and results: From January 2009 to June 2014, 256 consecutive CRT patients (mean age 68.3±11.6years, 216 male, 88% in New York Heart Association class II-IV, ejection fraction 35.1±10.8%) were treated at four European institutions with TLE. Indications for TLE included systemic (18%) or local (45%) infection, system malfunction (34%), or other (3%). Demographic, clinical, TLE procedural, and follow-up data were collected retrospectively. Adverse events (AE) were considered as death from any cause, cardiovascular hospitalization, and SAE (SAE included pocket and/or systemic infection, lead malfunction, or pocket haematoma requiring revision). Complete removal was achieved for 607 out of 614 leads (98.9%) by using either manual traction (29%), mechanical (43%) or laser (28%) sheaths. Over a median follow-up of 21 (interquartile range 12-29) months, cumulative incidences of any AE and SAE were 39.8% and 21.5%, respectively. Recurring system malfunction occurred in 23 patients (9.0%), infection in 17 patients (6.6%), and pocket haematoma requiring revision in 15 patients (5.9%). Oral anticoagulation therapy was an independent predictor of both any AE [hazard ratio (HR) 2.09, 95% confidence interval (CI) 1.35-3.22, P
KW - Cardiac resynchronization therapy
KW - Device-related adverse events
KW - Lead management
KW - Transvenous lead extraction
UR - http://www.scopus.com/inward/record.url?scp=84969895398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969895398&partnerID=8YFLogxK
U2 - 10.1002/ejhf.558
DO - 10.1002/ejhf.558
M3 - Article
C2 - 27170594
AN - SCOPUS:84989929978
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
ER -